Member Info for Jarv55

worth a listen https://www.youtube.com/watch?v=ONDjwcCyroI

Take a look at this video explains what the mms are doing here
https://www.youtube.com/watch?v=h1WaZHO7C3k

Check out some of the brands liking this https://www.linkedin.com/feed/update/urn:li:activity:6704052195681153024/

https://gulfbusiness.com/dubais-emirates-nbd-launches-new-digital-supply-chain-financing-platform/?fbclid=IwAR3qcxLvyGdaQ1FRoIxcidpFGuGK9DydRQVlZtzkSCpCEKGPHlA_35WlhEw

Worth a read https://business.express/debt-equity-and-how-the-future-of-business-finance-may-not-be-finance-at-all/ explains the model

https://invst.ly/sd9ei bullish acending triangle just needs to clear the 200ma

They aren't messing about here watch for the big names to come on board.
https://www.fintechdirect.net/2020/10/05/italian-paytech-nexi-to-buy-sia-in-e4-5bn-deal/

Inventories are released thanks to the use of smart contracts and the use of the blockchain by Sia , the group specialized in payment infrastructures controlled by Cdp Equity and which will soon merge with the listed paytech Nexi (see another article by BeBeez). The possession of the inventories remains in the hands of the client company ,

Have a feeling the chance to top up at these levels is coming to an end added a few more roll on the news
https://invst.ly/scvpc

https://www.youtube.com/watch?v=5fFfNbtB8_k webinar from March
https://www.youtube.com/watch?v=5boGFctPCv0 worth a listen

https://invst.ly/scsfg targeting 52

Buy the dips while you can

P2F is an innovative Nanoparticle company. Their patents include a patent around the PROCESS of producing the nano particles (this process is generic) AND also the manner in which it is incorporated within organic compounds.

https://patents.justia.com/patent/20150027050

https://patents.google.com/patent/EP2825515A2/en

Video interview with chief scientist Dr Gareth Cave
https://m.youtube.com/watch?v=22pS6R78DUI

Gareth is part of a team of researchers at the Uni
https://www.ntu.ac.uk/staff-profiles/science-technology/gareth-cave

Chief Technical Officer at P2F is Karen Davies, note paper below: Nano particle feed gives higher yield, faster growth, better storage after harvests, improved taste and most importantly nutritionally better. This will reduce fertiliser use which I believe only a portion gets absorbed.

http://irep.ntu.ac.uk/id/eprint/35494/

Areas on which P2F is focussing:
Food security: nano feeds are patented “ NSitu”: improved yields, improved nutrition, better tasting and shorter cycles, less waste of fertilisers, longer shelf life
Pest resistance (Ex: Citrus greening disease or HLB which has reduced citrus fruit yield by 50% in last decade): We know zinc applied topically helps protect the orange trees, nanoparticulate zinc proven to be more effective as spray)
Hydroponics: vertical farming, Medicinal Cannabis market etc
Printable electronics/data storage/solar cells (with Flextronics)
Targeted delivery of drugs: cancer drug delivery is a focus
Innovation in medical imaging tech: Magnetic particle imaging (aiming to supercede MRI)
Last but not the least: nano particle application in COVID relevant areas: could include masks and potentially other surface coating....

16th September : Gyrometric Systems has successfully demonstrated proof of concept for a new single sensor torsional vibration monitor ("TVM"). TVM is a digital, portable contactless device. Being digital we believe, this device is more accurate than anything else currently available and because it is contactless it can be used without removing a mesh safety guard making it easier to use.

18th Sept. Pharm2 Farm has developed a second defensive layer that incorporates its own nanotechnology, which is engineered to kill viruses and bacteria. Combining this new active layer with the physical barrier layer, to produce four layer (ply) masks, is expected to improve user safety over a prolonged use. This new material is currently undergoing testing, specifically, with respect to the time taken to kill viruses, including COVID-19. These tests are, being undertaken at the University of Nottingham and results are expected by the beginning of October.

01-Oct-20 11:07:16 0.46273 20,000,000 Buy* 0.44 0.46 92.55k O

Mikey thanks for your indepth research there quick everyone take notice of Mikey lol

Partnership with leading Ad-tech tech provider



Iconic Labs Plc (LSE:ICON), a multidivisional new media and technology business, today announces that after a successful trial Iconic Labs has signed a commercial partnership agreement with Glimpse Protocol, a leading provider of advanced technologies to Ad-tech.

This partnership will allow Iconic Labs to be well positioned to become industry leaders in the cookieless advertising space and future proof this part of the Company's business. Glimpse Protocol will benefit from Iconic Labs advertising experience and access to multiple platforms, including to trial their technology.

Glimpse Protocol will compete for programmatic inventory on the Iconic Labs platforms with other advertisers and will not receive any discount to market rate. This offering will allow programmatic advertisers to comply with GDPR and internal policies while still conducting effective advertising.

Iconic Labs will use the Glimpse Protocol's technology on all of their owned and operated platforms including JOE Media where the Glimpse Protocol platform will be tested and monitored in real time. The Glimpse Protocol platform is currently live on TLE, protecting 1.5million readers so far from their browsing information being obtained by other parties.

In addition to the operational benefits that it provides, it has been agreed that warrants will be issued to Iconic Labs in recognition of their market access and wider advisory support. The warrants entitle Iconic Labs to subscribe for such number of ordinary shares in the capital of Glimpse Protocol, which shall be equal to 1.25% of its issued equity and which are exercisable at a discount to the subscription price payable for ordinary shares on any future sale or capital raise undertaken by Glimpse Protocol.

Glimpse Protocol are a market leader in data protection using frontier technologies. Their cookieless platform uses two forms of advanced cryptography to protect consumers' personal internet browsing data from being seen, read, transferred, sold or recycled by another party.

Google have recently announced within 2 years their chrome browser will no longer be using cookies which store personal browsing data on your PC/Phone. Apple have also taken a similar approach with their safari browser.

Samuel Regan Asante COO of Iconic Labs - "We are very pleased to announce a partnership with Glimpse Protocol who are leading the way in cookie-less technologies within the AdTech industry. Iconic Labs is aiming to establish itself as a leader in both the tech and media fields and Glimpse Protocol's technology presents the perfect balance of the two. With Glimpse Protocol's existing partnership with The Founder's Factory we're excited about their future as a leader in the industry."

I wonder if the government will announce this today as its part of their moonshot plan

Graham Mullis, Chief Executive Officer of Novacyt, added:



"I am delighted that Novacyt continues to play a key role in helping the UK fight the COVID-19 pandemic and this second DHSC contract reinforces the Company's important position within UK diagnostics today. Through this contract, we will be working to support the NHS as we approach an expected challenging winter period. The ability to test multiple patients with our market leading COVID-19 kits and instruments designed to provide results in under 60 minutes will help to ensure vital NHS services can continue to function during these difficult times. I am immensely proud of what the Novacyt team continues to deliver and remain confident in the prospects of the business, not only for the short-term, but also for the longer-term."

The second phase of the contract, which is optional by the DHSC, allows for the provision of up to 700 additional PCR instruments, related kits and support services, as well as additional COVID-19 products from the Company's portfolio where required. Depending upon the uptake, phase two of the contract could generate considerably more sales than the first phase.



The intended use of the contract is for Novacyt to support the urgent requirement for COVID-19 testing of patients in the NHS. In addition to the provision of products, the Company will also provide training and maintenance services for the q16 and q32 instrument platforms.



Novacyt has the capacity to meet the demand of both phases of this new contract, as well as to continue to build its sales across international markets.

I wonder if they will give out dividends really should be on the Nasdaq

New contract with UK DHSC for instrument platforms and COVID-19 testing kits



Paris, France and Camberley, UK - 29 September 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces it has signed a new supply contract with the UK Department of Health and Social Care (DHSC) for its q16 and q32 Rapid-PCR instrument platforms, exsig® COVID-19 Direct kits and genesig® SARS-CoV-2 Winterplex kits.



This is the second major contract awarded by the DHSC to Primerdesign, the Company's wholly owned molecular diagnostics division, during the COVID-19 pandemic and follows the ongoing contract announced on 27 April 2020 for the supply of its PCR COVID-19 test.



Under the terms of the contract, which is in two phases, Primerdesign will supply its products to the DHSC for up to six months. Phase one has an initial fixed term of 14 weeks with the potential to extend supply by a further 10 weeks. This first phase of the contract will involve the immediate deployment of 300 PCR instruments, related kits and support services with a minimum value of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC.